Patients with myocardial infarction (MI) characterized by ST-segment elevation who are treated with the blood thinner enoxaparin, a low-molecular-weight heparin, plus a clot dissolver are significantly less likely to die or have a repeat MI within 30 days than patients receiving unfractionated heparin, say Harvard Medical School investigators.
The findings appear in the March 5 issue of Circulation: Journal of the American Heart Association. Elliott Antman, MD, an author of the report and associate professor of medicine at Harvard, called for a larger clinical trial to determine whether enoxaparin should be standard treatment for severe MI. Enoxaparin has been shown to be superior to unfractionated heparin for patients with milder MI (without ST-segment elevation).
Mitka M. Better Heparin for Severe MI? JAMA. 2002;287(12):1518. doi:10.1001/jama.287.12.1518
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: